64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

计划入组 54 人 · 首次发布于 2021 年 5 月 3 日

Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)

计划入组 30 人 · 首次发布于 2021 年 4 月 9 日

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

计划入组 52 人 · 首次发布于 2022 年 2 月 21 日

64Cu-SAR-bisPSMA

67Cu-SAR-bisPSMA

64Cu-SAR-bisPSMA (Clarity Pharmaceuticals)

BSPSPA PTY LTD

Australia

PHARMA MAR SA

Spain

HOSPITAL SAO DOMINGOS SA

Brazil

Clarity Pharmaceuticals' 67Cu-SAR-bisPSMA Shows Promise in mCRPC Trial

Clarity Pharmaceuticals and Nucleus RadioPharma Collaborate on 67Cu-SAR-bisPSMA Phase 3 Trial

Clarity's 64Cu-SAR-bisPSMA Shows Promise in Detecting Prostate Cancer Recurrence in COBRA Trial